{"id":"W4385581025","doi":"10.1158/2159-8290.c.6734381.v2","title":"Data from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Neutropenia; Antagonist; Vomiting; Medicine; Nausea; Adverse effect; Internal medicine; In vivo; Limiting; Pharmacokinetics; Gastroenterology; Liposarcoma; Pharmacology; Oncology; Chemotherapy; Sarcoma; Pathology; Biology; Receptor; Biotechnology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001510893,0.0008394507,0.001693864,0.0003032537,0.0003842241,0.0008808043,0.0005948613,0.0006808359,0.003653247],"category_scores_gemma":[0.001124128,0.0003303772,0.001257745,0.0005921086,0.0004045746,0.0005449592,0.0002693748,0.002121727,0.001023896],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006878059,"about_ca_system_score_gemma":0.0009163482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001248045,"about_ca_topic_score_gemma":0.003884541,"domain_scores_codex":[0.9994131,0.0002735842,0.00005941503,0.00007369054,0.0001098647,0.00007026546],"domain_scores_gemma":[0.9988922,0.0002443954,0.0002925917,0.0001158055,0.0001094255,0.0003455717],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4158606,0.03163132,0.02997013,0.003362549,0.004247061,0.0007934794,0.000531856,0.007486496,0.1898323,0.0004391536,0.0313969,0.2844481],"study_design_scores_gemma":[0.250252,0.4839542,0.1719192,0.0003233293,0.004469331,0.001969964,0.000279069,0.00342003,0.0306187,0.0005445632,0.05209746,0.0001522208],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.964731,0.01104831,0.00119609,0.001253695,0.0001520887,0.001900667,0.01107332,0.0002230876,0.008421805],"genre_scores_gemma":[0.972701,0.005769215,0.0012719,0.001694083,0.0001410007,0.001067024,0.01389669,0.00008298111,0.00337625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003653247,"threshold_uncertainty_score":0.01222134,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07316352570795866,"score_gpt":0.3753780830367726,"score_spread":0.3022145573288139,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}